
    
      This Phase 4 study is designed to demonstrate noninferiority of pretreatment with Hylenex
      recombinant in the CSII setting to rapid-acting analog insulin alone with respect to glycemic
      control as assessed by changes in HbA1c in participants with Type 1 diabetes mellitus.

      Total duration of study treatment is 24 months. However, according to the study design, the
      primary outcome measure is to be assessed at 6 months and an interim analysis is to be
      completed at 6 months for the secondary outcome measures and adverse events. Therefore, data
      reported in this clinical trials record is for the 6-month interim analysis.
    
  